C. Crumpacker

C. Crumpacker, J. Timpone, J. Holden-Wiltse, 1996, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

Successful treatment with foscarnet of an acyclovir-resistant mucocutaneous infection with herpes simplex virus in a patient with acquired immunodeficiency syndrome.

C. Crumpacker, C. Miller, P. Chatis, 1989, The New England journal of medicine.

Treatment of Cytomegalovirus Infections

C. Crumpacker, 1989 .

Ineffectiveness of topical adenine arabinoside 5'-monophosphate in the treatment of recurrent herpes simplex labialis.

C. Crumpacker, M. Klauber, S. Spruance, 1979, The New England journal of medicine.

Resistance of herpes simplex virus to acycloguanosine: role of viral thymidine kinase and DNA polymerase loci.

C. Crumpacker, L. Schnipper, 1980, Proceedings of the National Academy of Sciences of the United States of America.

New anti-HSV therapeutics target the helicase–primase complex

C. Crumpacker, P. Schaffer, 2002, Nature Medicine.

Analysis of the thymidine kinase gene from clinically isolated acyclovir-resistant herpes simplex viruses.

C. Crumpacker, P. Chatis, 1991, Virology.

Varicella-zoster virus disease in patients with human immunodeficiency virus infection.

C. Crumpacker, R. Gulick, M. Heath-Chiozzi, 1990, Archives of dermatology.

Sorivudine versus Acyclovir for Treatment of Dermatomal Herpes Zoster in Human Immunodeficiency Virus-Infected Patients: Results from a Randomized, Controlled Clinical Trial

C. Crumpacker, S. Soong, R. Steigbigel, 1998, Antimicrobial Agents and Chemotherapy.

Rapid and Durable Antiretroviral Effect of the HIV-1 Integrase Inhibitor Raltegravir as Part of Combination Therapy in Treatment-Naive Patients With HIV-1 Infection: Results of a 48-Week Controlled Study

C. Crumpacker, C. Kovacs, H. Teppler, 2007, Journal of acquired immune deficiency syndromes.

Treatment of cytomegalovirus pneumonia.

C. Crumpacker, S. Abrams, S. Marlowe, 1988, Reviews of infectious diseases.

Prolonged continuous acyclovir treatment of normal adults with frequently recurring genital herpes simplex virus infection

C. Crumpacker, P. Frost, L. Davis, 1991, JAMA.

Treatment of Viral Infections in the Human Immunodeficiency Virus-Infected Patient

C. Crumpacker, R. Gulick, 1994 .

Effects of the nucleoside analog 2'-nor-2'-deoxyguanosine on human cytomegalovirus replication

C. Crumpacker, H. Perry, M. Tocci, 1984, Antimicrobial Agents and Chemotherapy.

Ganciclovir treatment of cytomegalovirus colitis in AIDS: a randomized, double-blind, placebo-controlled multicenter study.

C. Crumpacker, D. Dieterich, D. Kotler, 1993, The Journal of infectious diseases.

Inactivation of Herpes Simplex Virus with Methylene Blue, Light and Electricity

C. Crumpacker, A. Lewin, L. Schnipper, 1979, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

Prolonged continuous acyclovir treatment of normal adults with frequently recurring genital herpes simplex virus infection

C. Crumpacker, P. Frost, L. Davis, 1992, JAMA.

Comparison of Quantitative and Qualitative PCR Assays for Cytomegalovirus DNA in Plasma

C. Crumpacker, S. Spector, N. Lurain, 2001, Journal of Clinical Microbiology.

A Standardized Plaque Reduction Assay for Determination of Drug Susceptibilities of Cytomegalovirus Clinical Isolates

C. Crumpacker, S. Spector, W. Britt, 2000, Antimicrobial Agents and Chemotherapy.

Guidelines for preventing opportunistic infections among HIV-infected persons - 2002

Keiji Fukuda, Mark A. Jacobson, Cynthia L. Sears, 2002 .

Resistance of herpesviruses to antiviral drugs

C. Crumpacker, P. Chatis, 1992, Antimicrobial Agents and Chemotherapy.

MINIREVIEW Resistance of Herpesviruses to Antiviral Drugs

C. Crumpacker, P. Chatis, 2022 .

MINIREVIEW Resistance ofHerpesviruses toAntiviral Drugs

C. Crumpacker, Pamela A. Chatisand, 1992 .

Mechanisms of photodynamic inactivation of herpes simplex viruses: comparison between methylene blue, light plus electricity, and hematoporhyrin plus light.

C. Crumpacker, A. Lewin, L. Schnipper, 1980, The Journal of clinical investigation.

Inhibition of immune functions by antiviral drugs.

C. Crumpacker, R. Finberg, W. Heagy, 1991, The Journal of clinical investigation.

Topical 5 percent acyclovir in polyethylene glycol for herpes simplex labialis. Antiviral effect without clinical benefit.

C. Crumpacker, S. Spruance, 1982, The American journal of medicine.

Primitive hematopoietic cells resist HIV-1 infection via p21.

C. Crumpacker, D. Scadden, Jielin Zhang, 2007, The Journal of clinical investigation.

Reverse transcriptase mutation K65N confers a decreased replication capacity to HIV-1 in comparison to K65R due to a decreased RT processivity.

C. Crumpacker, P. L. Sharma, Himabindu Chunduri, 2011, Virology.

A randomized placebo-controlled trial of recombinant human interferon alpha 2a in patients with aids

R. Schooley, C. Crumpacker, H. Handsfield, 1988 .

Treatment of herpes simplex labialis with topical acyclovir in polyethylene glycol.

C. Crumpacker, K. Arndt, J. Modlin, 1982, The Journal of infectious diseases.

Low Rate of CMV End-Organ Disease in HIV-Infected Patients Despite Low CD4+ Cell Counts and CMV Viremia: Results of ACTG Protocol A5030

C. Crumpacker, S. Spector, D. Jabs, 2009, HIV clinical trials.

Incorporation of 1-beta-D-arabinofuranosylcytosine into DNA and mutagenesis of herpes simplex virus type 1

C. Crumpacker, G. Bubley, L. Schnipper, 1986, Antimicrobial Agents and Chemotherapy.

Incorporation of 1-3-D-Arabinofuranosylcytosine into DNA and Mutagenesis of Herpes Simplex Virus Type 1

C. Crumpacker, G. Bubley, L. Schnipper, 2022 .

Incorporation of 1-/ 3-D-Arabinofuranosylcytosine into DMA from Herpes Simplex Virus Resistant to 9-0D-Arabinofuranosyladenine 1

C. Crumpacker, D. Kufe, L. Schnipper, 2006 .

Molecular targets of antiviral therapy.

C. Crumpacker, 1989, The New England journal of medicine.

Resistance of herpes simplex virus to adenine arabinoside and E-5-(2-bromovinyl)-2'-deoxyuridine: a physical analysis.

C. Crumpacker, L. Schnipper, P. Kowalsky, 1982, The Journal of infectious diseases.

Genetic mechanisms of resistance to acyclovir in herpes simplex virus.

C. Crumpacker, L. Schnipper, P. Chartrand, 1982, The American journal of medicine.

Two regions of the herpes simplex virus type 1 UL42 protein are required for its functional interaction with the viral DNA polymerase

C. Crumpacker, D. Parris, S. J. Monahan, 1993, Journal of virology.

Localization of the herpes simplex virus type 1 65-kilodalton DNA-binding protein and DNA polymerase in the presence and absence of viral DNA synthesis

C. Crumpacker, D. Parris, P. Schaffer, 1990, Journal of virology.

The essential 65-kilodalton DNA-binding protein of herpes simplex virus stimulates the virus-encoded DNA polymerase

C. Crumpacker, D. Parris, D. Dorsky, 1989, Journal of virology.

Ribavirin treatment of murine coxsackievirus B3 myocarditis with analyses of lymphocyte subsets.

W. Abelmann, C. Crumpacker, C. Kishimoto, 1988, Journal of the American College of Cardiology.

2'-Nor-cGMP: a seco-cyclic nucleotide with powerful anti-DNA-viral activity.

C. Crumpacker, J. D. Karkas, E. Scolnick, 1985, Biochemical and biophysical research communications.

Effect of foscarnet on quantities of cytomegalovirus and human immunodeficiency virus in blood of persons with AIDS

W. K. Henry, C. Crumpacker, H. Balfour, 1996, Antimicrobial agents and chemotherapy.

Phase II dose‐ranging trial of foscarnet salvage therapy for cytomegalovirus retinitis in AIDS patients intolerant of or resistant to ganciclovir (ACTG Protocol 093)

Roger B. Davis, M. Wulfsohn, C. Crumpacker, 1994 .

Mutations conferring foscarnet resistance in a cohort of patients with acquired immunodeficiency syndrome and cytomegalovirus retinitis.

C. Crumpacker, D. Jabs, S. Chou, 2003, The Journal of infectious diseases.

Inhibition of HSV-transformed murine cells by nucleoside analogs, 2'-NDG and 2'-nor-cGMP: mechanisms of inhibition and reversal by exogenous nucleosides.

C. Crumpacker, G. Bubley, S. Oliver, 1985, Virology.

Inhibition of herpes simplex virus transformed and nontransformed cells by acycloguanosine: mechanisms of uptake and toxicity.

C. Crumpacker, L. Schnipper, R. Davidson, 1981, Virology.

Ribavirin antagonizes the effect of azidothymidine on HIV replication

R. Schooley, M. Hirsch, C. Crumpacker, 1987, Science.

Absence of antibodies to HTLV-III in health workers after hepatitis B vaccination.

C. Crumpacker, R. Platt, D. Snydman, 1985, JAMA.

A Leu to Ile but not Leu to Val change at HIV-1 reverse transcriptase codon 74 in the background of K65R mutation leads to an increased processivity of K65R+L74I enzyme and a replication competent virus

C. Crumpacker, D. Rimland, P. L. Sharma, 2011, Virology Journal.

Isolated antibody to hepatitis B surface antigen and response to hepatitis B vaccination.

C. Crumpacker, R. Platt, D. Snydman, 1985, Annals of internal medicine.

Early, patient-initiated treatment of herpes labialis with topical 10% acyclovir

C. Crumpacker, K. Arndt, S. Spruance, 1984, Antimicrobial Agents and Chemotherapy.

Significance of resistance of herpes simplex virus to acyclovir.

C. Crumpacker, 1988, Journal of the American Academy of Dermatology.

Dideoxynucleoside resistance emerges with prolonged zidovudine monotherapy. The RV43 Study Group

S. Hammer, C. Crumpacker, G. Mcleod, 1994, Antimicrobial Agents and Chemotherapy.

Immunologic Responses to Hepatitis B Virus and their Interpretations

C. Crumpacker, R. Platt, D. Snydman, 1984 .

Studies of Nondefective Adenovirus 2-Simian Virus 40 Hybrid Viruses. VI. Characterization of the DNA from Five Nondefective Hybrid Viruses

C. Crumpacker, A. Levine, L. Schnipper, 1973, Journal of virology.

Studies of Nondefective Adenovirus 2-Simian Virus 40 Hybrid Viruses IV. Characterization of the Simian Virus 40 Ribonucleic Acid Species Induced by Wild-Type Simian Virus 40 and by the Nondefective Hybrid Virus, Ad2+ND1

C. Crumpacker, M. Levin, A. Levine, 1971, Journal of virology.

Increased sensitivity of thymidine kinase-deficient (TK-) tumor cell lines to the cell growth inhibitory effects of (E)-5-(2-bromovinyl)-2'-deoxyuridine (BVDU) and related compounds.

C. Crumpacker, E. De Clercq, T. Seno, 1986, Anticancer research.

Attenuated replication of human immunodeficiency virus type 1 with a didanosine-selected reverse transcriptase mutation

C. Crumpacker, P. L. Sharma, P. Sharma, 1997, Journal of virology.

Incorporation of 1-beta-D-arabinofuranosylcytosine into DNA from herpes simplex virus resistant to 9-beta-D-arabinofuranosyladenine.

C. Crumpacker, D. Kufe, L. Schnipper, 1984, Cancer research.

Expression of the CD8alpha beta-heterodimer on CD8(+) T lymphocytes in peripheral blood lymphocytes of human immunodeficiency virus- and human immunodeficiency virus+ individuals.

C. Crumpacker, R. Gelman, J. Schmitz, 1998, Blood.

Expression of the CD 8 ab-Heterodimer on CD 8 1 T Lymphocytes in Peripheral Blood Lymphocytes of Human Immunodeficiency Virus 2 and Human Immunodeficiency Virus 1 Individuals

C. Crumpacker, R. Gelman, J. Schmitz, 1998 .

Hematopoietic Stem and Immune Cells in Chronic HIV Infection

C. Crumpacker, Jielin Zhang, 2015, Stem cells international.

Zidovudine Compared With Didanosine in Patients With Advanced HIV Type I Infection and Little or No Previous Experience With Zidovudine

K. K. Lai, D. Katzenstein, M. Hirsch, 1995 .

Silencing p21Waf1/Cip1/Sdi1 expression increases gene transduction efficiency in primitive human hematopoietic cells

C. Crumpacker, J Zhang, D. Scadden, 2005, Gene Therapy.

Studies of Nondefective Adenovirus 2-Simian Virus 40 Hybrid Viruses V. Isolation of Additional Hybrids Which Differ in Their Simian Virus 40-Specific Biological Properties

C. Crumpacker, M. Levin, A. Levine, 1973, Journal of virology.

Rapid Ganciclovir Susceptibility Assay Using Flow Cytometry for Human Cytomegalovirus Clinical Isolates

C. Crumpacker, G. Drusano, H. Shapiro, 1998, Antimicrobial Agents and Chemotherapy.

Flow Cytometric Determination of Ganciclovir Susceptibilities of Human Cytomegalovirus Clinical Isolates

C. Crumpacker, G. Drusano, N. Lurain, 1998, Journal of Clinical Microbiology.

Human Immunodeficiency Virus Type 1 Nucleocapsid Protein Nuclear Localization Mediates Early Viral mRNA Expression

C. Crumpacker, Jielin Zhang, 2002, Journal of Virology.

Enhancement of the basal-level activity of HIV-1 long terminal repeat by HIV-1 nucleocapsid protein.

C. Crumpacker, P. Sharma, J. Zhang, 2000, Virology.

Human immunodeficiency virus type 1 RNA in peripheral blood mononuclear cells of patients receiving prolonged highly active antiretroviral therapy.

C. Crumpacker, J. Zhang, Jielin Zhang, 2001, The Journal of infectious diseases.

Association of plasma human immunodeficiency virus type 1 RNA level with risk of clinical progression in patients with advanced infection. AIDS Clinical Trials Group (ACTG) 116B/117 Study Team. ACTG Virology Committee Resistance and HIV-1 RNA Working Groups.

J. Kahn, D. Richman, C. Crumpacker, 1996, The Journal of infectious diseases.

Coxsackievirus B infection in pregnant mice and transplacental infection of the fetus

C. Crumpacker, J. Modlin, 1982, Infection and immunity.

Treatment of viral myocarditis with ribavirin in an animal preparation.

W. Abelmann, C. Crumpacker, A. Matsumori, 1985, Circulation.

Use of virologic assays for detection of human immunodeficiency virus in clinical trials: recommendations of the AIDS Clinical Trials Group Virology Committee

S. Hammer, C. Crumpacker, R. D’Aquila, 1993, Journal of clinical microbiology.

The effect of tenidap on cytokines, acute-phase proteins, and virus load in human immunodeficiency virus (HIV)-infected patients: correlation between plasma HIV-1 RNA and proinflammatory cytokine levels.

M. Lederman, C. Crumpacker, S. Silberman, 1997, The Journal of infectious diseases.

Prognostic value of plasma human immunodeficiency virus type 1 (HIV-1) RNA levels in patients with advanced HIV-1 disease and with little or no prior zidovudine therapy

J. Kahn, D. Richman, C. Crumpacker, 1996 .

Prognostic value of plasma human immunodeficiency virus type 1 (HIV-1) RNA levels in patients with advanced HIV-1 disease and with little or no prior zidovudine therapy. AIDS Clinical Trials Group Protocol 116A/116B/117 Team.

J. Kahn, D. Richman, C. Crumpacker, 1996, The Journal of infectious diseases.

The interleukin-2 fusion protein, DAB389IL-2, inhibits the development of infectious virus in human immunodeficiency virus type 1-infected human peripheral blood mononuclear cells.

C. Crumpacker, L. Poisson, L. Estis, 1997, The Journal of infectious diseases.

Toward a Cure: Does Host Immunity Play a Role?

C. Crumpacker, Jielin Zhang, 2017, mSphere.

Treatment ofviral myocarditis withribavirin inan animal preparation

C. Crumpacker, 1985 .

Zidovudine Resistance and HIV-1 Disease Progression during Antiretroviral Therapy

D. Richman, C. Crumpacker, V. Johnson, 1995, Annals of Internal Medicine.

Prevalence and Clinical Significance of Zidovudine Resistance Mutations in Human Immunodeficiency Virus Isolated from Patients after Long-Term Zidovudine Treatment

D. Richman, C. Crumpacker, V. Johnson, 1995 .

Propranolol ameliorates and epinephrine exacerbates progression of acute and chronic viral myocarditis.

W. Abelmann, C. Crumpacker, I. Amende, 2005, American journal of physiology. Heart and circulatory physiology.

Adenovirus Type 2-Simian Virus 40 Hybrid Population: Evidence for a Hybrid Deoxyribonucleic Acid Molecule and the Absence of Adenovirus-Encapsidated Circular Simian Virus 40 Deoxyribonucleic Acid

C. Crumpacker, M. Levin, W. Wiese, 1970, Journal of virology.

Decreased Processivity of Human Immunodeficiency Virus Type 1 Reverse Transcriptase (RT) Containing Didanosine-Selected Mutation Leu74Val: a Comparative Analysis of RT Variants Leu74Val and Lamivudine-Selected Met184Val

C. Crumpacker, P. L. Sharma, 1999, Journal of Virology.

Studies of Nondefective Adenovirus 2-Simian Virus 40 Hybrid Viruses III. Base Composition, Molecular Weight, and Conformation of the Ad2+ND1 Genome

C. Crumpacker, M. Levin, W. Rowe, 1971, Journal of virology.

Phase I Studies of Hypericin, the Active Compound in St. John's Wort, as an Antiretroviral Agent in HIV-Infected Adults: AIDS Clinical Trials Group Protocols 150 and 258

C. Crumpacker, J. Holden-Wiltse, F. Valentine, 1999, Annals of Internal Medicine.

Overview of cytomegalovirus infections in HIV-infected patients: current therapies and future strategies.

C. Crumpacker, M. Heath-Chiozzi, 1991, Journal of acquired immune deficiency syndromes.

Prevention of encephalomyocarditis virus myocarditis in mice by inactivated virus vaccine

W. Abelmann, C. Crumpacker, A. Matsumori, 1985, Heart and Vessels.

Detection of human immunodeficiency virus type 1 clinical isolates with reduced sensitivity to zidovudine and dideoxyinosine by RNA.RNA hybridization.

C. Crumpacker, P. Chatis, A. Japour, 1991, Proceedings of the National Academy of Sciences of the United States of America.

METHODS Virus Preparation and Inoculation of Mice The M variant of EMCV ( American Type Culture

W. Abelmann, C. Crumpacker, I. Amende, 2005 .

Combination of ganciclovir and granulocyte-macrophage colony-stimulating factor in the treatment of cytomegalovirus retinitis in AIDS patients

C. Crumpacker, S. Spector, B. Polsky, 2005, European Journal of Clinical Microbiology and Infectious Diseases.

Hematopoietic stem and progenitor cells in HIV/AIDS and immune reconstitution

C. Crumpacker, Jielin Zhang, 2010, Cell Research.

Naive and memory CD4⁺ T cells in HIV eradication and immunization.

C. Crumpacker, M. Poznansky, Jielin Zhang, 2012, The Journal of infectious diseases.

A nondefective (competent) adenovirus-SV40 hybrid isolated from the AD.2-SV40 hybrid population.

C. Crumpacker, M. Levin, A. M. Lewis, 1969, Proceedings of the National Academy of Sciences of the United States of America.

Studies ofNondefective Adenovirus 2-Simian Virus 40Hybrid Viruses III. BaseComposition, Molecular Weight, andConformation oftheAd2+ND1Genome

C. Crumpacker, M. Levin, A. Lewis, 1971 .

Virus replication and induction of interferon in human epidermal keratinocytes following infection with herpes simplex virus.

C. Crumpacker, B. Gilchrest, L. Schnipper, 1984, The Journal of investigative dermatology.

Prevalence and clinical significance of zidovudine resistance mutations in human immunodeficiency virus isolated from patients after long-term zidovudine treatment. AIDS Clinical Trials Group 116B/117 Study Team and the Virology Committee Resistance Working Group.

J. Kahn, D. Richman, C. Crumpacker, 1995, The Journal of infectious diseases.

Drug resistance in cytomegalovirus: current knowledge and implications for patient management.

C. Crumpacker, 1996, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

Pathogenesis and preventive and therapeutic trials in an animal model of dilated cardiomyopathy induced by a virus.

W. Abelmann, C. Crumpacker, A. Matsumori, 1987, Japanese circulation journal.

The effect of (E)-5-(2-bromovinyl)-2'-deoxyuridine on DNA repair and mutagenesis of herpes simplex virus type 1.

C. Crumpacker, E. De Clercq, G. Bubley, 1987, Virology.

Ganciclovir for treatment of renal transplant-associated primary cytomegalovirus pneumonia.

C. Crumpacker, D. Snydman, D. Hecht, 1988, The Journal of infectious diseases.

Comparison of Molecular Tests for Detection and Quantification of Cell-Associated Cytomegalovirus DNA

C. Crumpacker, A. Caliendo, S. Spector, 2003, Journal of Clinical Microbiology.

Resistance of Herpes Simplex Virus to Antiviral Agents

C. Crumpacker, 1983, Drugs.

Studies ofNondefective Adenovirus 2-Simian Virus 40Hybrid Viruses IV.Characterization oftheSimian Virus40Ribonucleic AcidSpecies Induced byWild-Type Simian Virus40andbytheNondefective HybridVirus, Ad2+ND1

C. Crumpacker, M. Levin, A. Levine, 1971 .